Evidence map›Paper›PMID 33653328›Full record

ArticleRespiratory research2021

IL-4Rα blockade reduces influenza-associated morbidity in a murine model of allergic asthma.

Kimia Shahangian, David A Ngan, H H Rachel Chen, Yeni Oh, Anthony Tam, Jing Wen, Chung Cheung, Darryl A Knight, Delbert R Dorscheid, Tillie L Hackett and 6 more

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Respiratory research, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
0.2field-weighted citation impact, top 48% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed, 5 citations in OpenAlex.

  1. Article
  2. Article
  3. The role of innate immune system in respiratory viral infection related asthma.Frontiers in cellular and infection microbiology · 2025
    Review
  4. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

16 authors at 2 institutions in 2 countries.

Kimia ShahangianCentre for Heart Lung Innovation, St. Paul's Hospital, University of British Columbia, Room 166, 1081 Burrard Street, Vancouver, BC, V6Z 1Y6, Canada.
David A NganCentre for Heart Lung Innovation, St. Paul's Hospital, University of British Columbia, Room 166, 1081 Burrard Street, Vancouver, BC, V6Z 1Y6, Canada.
H H Rachel ChenCentre for Heart Lung Innovation, St. Paul's Hospital, University of British Columbia, Room 166, 1081 Burrard Street, Vancouver, BC, V6Z 1Y6, Canada.
Yeni OhCentre for Heart Lung Innovation, St. Paul's Hospital, University of British Columbia, Room 166, 1081 Burrard Street, Vancouver, BC, V6Z 1Y6, Canada.
Anthony TamCentre for Heart Lung Innovation, St. Paul's Hospital, University of British Columbia, Room 166, 1081 Burrard Street, Vancouver, BC, V6Z 1Y6, Canada.
Jing WenCentre for Heart Lung Innovation, St. Paul's Hospital, University of British Columbia, Room 166, 1081 Burrard Street, Vancouver, BC, V6Z 1Y6, Canada.
Chung CheungCentre for Heart Lung Innovation, St. Paul's Hospital, University of British Columbia, Room 166, 1081 Burrard Street, Vancouver, BC, V6Z 1Y6, Canada.
Darryl A KnightCentre for Heart Lung Innovation, St. Paul's Hospital, University of British Columbia, Room 166, 1081 Burrard Street, Vancouver, BC, V6Z 1Y6, Canada.
Delbert R DorscheidCentre for Heart Lung Innovation, St. Paul's Hospital, University of British Columbia, Room 166, 1081 Burrard Street, Vancouver, BC, V6Z 1Y6, Canada.
Tillie L HackettCentre for Heart Lung Innovation, St. Paul's Hospital, University of British Columbia, Room 166, 1081 Burrard Street, Vancouver, BC, V6Z 1Y6, Canada.
Michael R HughesDepartment of Medicine, University of British Columbia, Vancouver, BC, Canada.
Kelly M McNagnyCentre for Heart Lung Innovation, St. Paul's Hospital, University of British Columbia, Room 166, 1081 Burrard Street, Vancouver, BC, V6Z 1Y6, Canada.
Jeremy A HirotaCentre for Heart Lung Innovation, St. Paul's Hospital, University of British Columbia, Room 166, 1081 Burrard Street, Vancouver, BC, V6Z 1Y6, Canada.
Masahiro NiikuraDepartment of Health Sciences, Simon Fraser University, Vancouver, BC, Canada.
S F Paul ManCentre for Heart Lung Innovation, St. Paul's Hospital, University of British Columbia, Room 166, 1081 Burrard Street, Vancouver, BC, V6Z 1Y6, Canada.
Don D SinCentre for Heart Lung Innovation, St. Paul's Hospital, University of British Columbia, Room 166, 1081 Burrard Street, Vancouver, BC, V6Z 1Y6, Canada. don.sin@hli.ubc.ca.ORCID http://orcid.org/0000-0002-0756-6643
University of British Columbia · CASimon Fraser University · CA

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundAsthma was identified as the most common comorbidity in hospitalized patients during the 2009 H1N1 influenza pandemic. We determined using a murine model of allergic asthma whether these mice experienced increased morbidity from pandemic H1N1 (pH1N1) viral infection and whether blockade of interleukin-4 receptor α (IL-4Rα), a critical mediator of T

methodsMale BALB/c mice were intranasally sensitized with house dust mite antigen (Der p 1) for 2 weeks; the mice were then inoculated intranasally with a single dose of pandemic H1N1 (pH1N1). The mice were administered intraperitoneally anti-IL-4Rα through either a prophylactic or a therapeutic treatment strategy.

resultsInfection with pH1N1 of mice sensitized to house dust mite (HDM) led to a 24% loss in weight by day 7 of infection (versus 14% in non-sensitized mice; p < .05). This was accompanied by increased viral load in the airways and a dampened anti-viral host responses to the infection. Treatment of HDM sensitized mice with a monoclonal antibody against IL-4Rα prior to or following pH1N1 infection prevented the excess weight loss, reduced the viral load in the lungs and ameliorated airway eosinophilia and systemic inflammation related to the pH1N1 infection.

conclusionTogether, these data implicate allergic asthma as a significant risk factor for H1N1-related morbidity and reveal a potential therapeutic role for IL-4Rα signalling blockade in reducing the severity of influenza infection in those with allergic airway disease.

Indexed as

AnimalsAntibodies, MonoclonalAsthmaDisease Models, AnimalHumansHypersensitivityInfluenza A Virus, H1N1 SubtypeInfluenza, HumanInterleukin-4 Receptor alpha SubunitMaleMiceMice, Inbred BALB CPyroglyphidaeReceptors, Cell SurfaceAntibodies, MonoclonalIl4ra protein, mouseInterleukin-4 Receptor alpha SubunitReceptors, Cell Surface

Identifiers

PMID33653328
PMCPMC7922715
OpenAlexW3134059441

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.